BFNH · XBRL financial data

Bioforce Nanosciences Holdings financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (BFNH's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
General and administrative	8	9*	25	9	16	17*	28	17	10	12*	12	119
Total operating expenses	114	114*	131	114	122	123*	133	123	116	118*	118	262
Operating income (loss)	—	—	—	(114)	(122)	—	(133)	(123)	(116)	—	—	—
Net income (loss)	(114)	(114)*	(131)	(114)	(122)	(123)*	(935)	(123)	(116)	(119)*	(102)	239
Earnings per share, basic USD per share	0.00	0.00*	0.00	0.00	0.00	0.00*	(0.03)	0.00	0.00	0.00*	0.00	0.01
Earnings per share, diluted USD per share	0.00	0.00*	0.00	0.00	0.00	0.00*	(0.03)	0.00	0.00	0.00*	0.00	0.01
Weighted average shares, basic thousands of shares	29,272	29,272*	29,272	29,272	29,272	29,272*	32,247	33,522	33,522	33,522*	33,522	33,544
Weighted average shares, diluted thousands of shares	29,272	29,272*	29,272	29,272	29,272	29,272*	32,247	33,522	33,522	33,522*	33,522	33,544

Fiscal quarters (BFNH's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1	1	1	1	2	1	14	1	1	1	6	0
Total current assets	1	1	1	1	2	1	14	1	1	1	6	2,154
Total assets	1	1	1	1	2	1	14	1	1	1	6	2,388
Total current liabilities	1,706	1,820	1,951	2,065	2,180	2,302	275	385	501	619	727	85
Total liabilities	1,706	1,820	1,951	2,065	2,180	2,302	275	385	501	619	727	85
Accumulated deficit	(160,515)	(160,630)	(160,761)	(160,875)	(160,997)	(161,120)	(162,055)	(162,178)	(162,294)	(162,412)	(162,515)	(162,276)
Total stockholders' equity	(1,705)	(1,819)	(1,950)	(2,064)	(2,178)	(2,302)	(261)	(384)	(500)	(619)	(721)	2,303
Total liabilities and equity	1	1	1	1	2	1	14	1	1	1	6	2,388
Common shares outstanding (cover page) thousands of shares	29,272	29,272	29,272	29,272	29,272	33,522	33,522	33,522	33,522	33,522	33,549	33,549

Fiscal quarters (BFNH's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(114)	(114)*	(131)	(114)	(122)	(123)*	(935)	(123)	(116)	(119)*	(102)	239
Net cash from operating activities	(8)*	(7)*	(18)	(13)*	(15)*	(15)*	(15)	(28)*	(11)*	(11)*	7	(27)*
Net cash from financing activities	8*	7*	18	13*	16*	14*	28	15*	11*	11*	(2)	21*
Net change in cash	0*	(0)*	0	0*	1*	(1)*	13	(13)*	(0)*	0*	6	(6)*

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Bioforce Nanosciences Holdings	0.3	not reported	(27)*	33.5M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Scientific Industries	617	1,470	(904)*	11.9M	5.0 quarters	Q2 FY26 10-QJun 30, 2026
Lifeloc Technologies	908	2,445	(133)*	2.8M	6.8 quarters	Q2 FY26 10-QJun 30, 2026
US Nuclear	67	352	(127)	62.8M	0.5 quarters	Q1 FY26 10-QMar 31, 2026
ASTROTECH	8,387	not reported	(2,288)*	2.0M	5.0 quarters	Q4 FY26 10-KJun 30, 2026
Electro Sensors	10,756	not reported	68	3.5M	—	Q1 FY26 10-QMar 31, 2026
Radnostix	1,196	2,672	(614)*	529.2M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Syntec Optics Holdings	14,047	8,274	(299)*	40.3M	47.0 quarters	Q2 FY26 10-QJun 30, 2026
Bionano Genomics	3,730	8,171	(4,670)*	11.8M	2.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.